Statement Of Cash Flows [Abstract]
| Concept |
2024-01-01 to 2024-12-31 |
2023-01-01 to 2023-12-31 |
|---|---|---|
| Statement of cash flows [abstract] | ||
| Cash flows from (used in) operating activities [abstract] | ||
| Cash flows from (used in) operations before changes in working capital |
3 728
SEK
|
5 311
SEK
|
| Adjustments for decrease (increase) in trade and other receivables |
4,000,000
SEK
|
899,000,000
SEK
|
| Adjustments for increase (decrease) in trade and other payables |
409,000,000
SEK
|
417,000,000
SEK
|
| Adjustments for gains (losses) on change in fair value less costs to sell, biological assets |
907,000,000
SEK
|
562,000,000
SEK
|
| Cash flows from (used in) investing activities [abstract] | ||
| Purchase of biological assets |
158,000,000
SEK
|
162,000,000
SEK
|
| Proceeds from sales of biological assets |
20,000,000
SEK
|
38,000,000
SEK
|
| Cash flows from (used in) financing activities [abstract] | ||
| Dividends paid to equity holders of parent, classified as financing activities |
1 831
SEK
|
2 592
SEK
|
| Repayments of non-current borrowings |
1 000
SEK
|
1 000
SEK
|
| Repayments of current borrowings |
112,000,000
SEK
|
64,000,000
SEK
|